Optimize Production of mRNA Therapeutics, from Clinical to Commercial
CleanCap® Reagents: A Novel mRNA Capping Solution
CleanCap technology is a “one-pot” solution that reduces the number of steps, equipment required, and time to produce a 5’ Cap 1 mRNA structure with 95% efficiency, providing a modern alternative to enzymatic capping. Available in GMP grade, CleanCap reagents offer an immediate solution for swiftly scaling from clinical to commercial.
Used in global commercial manufacturing programs, including a leading COVID-19 vaccine, CleanCap technology has proven to be the optimal mRNA vaccine capping method. See how we ramped up production to meet unprecedented demands in the global pandemic. View case study >
A New Level of Performance and Efficiency
See how the evolution of cap analogs led to the creation of CleanCap technology and the enablement of a single, co-transcriptional in vitro transcription reaction for manufacturing mRNA.
CleanCap technology is the fastest and easiest way to produce a 5’ Cap 1 mRNA structure with 95% efficiency. The “one-pot” solution requires fewer steps and less equipment than enzymatic capping—allowing for:
CleanCap reagents are advancing some of the most cutting-edge pharmaceuticals and biotechnologies on the market today. Recognized as the superior capping method, CleanCap analogs are the future of mRNA therapeutic production.